Glycosmedia Weekly Diabetes News Update
View this email in your browser

Platinum Sponsors:

Boehringer Ingelheim Lilly

Gold Sponsors:

Novo Nordisk

AstraZeneca

Silver Sponsors:
 

Abbott Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 11/27/2020

Glycemic control before admission is an important determinant of prognosis in patients with coronavirus disease 2019

HbA1c was an independent risk factor for poor outcomes in coronavirus disease 2019 patients. Severe pulmonary infection and consequent acute respiratory distress syndrome might be the primary causes of death in insufficient glycemic control patients (Journal of Diabetes Investigation)


Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by [18F]fluorodeoxyglucose PET‐MRI

Metformin dose is an independent determinant of FDG accumulation in the wall and lumen of the large intestine in individuals treated with this drug (Diabetes, Obesity and Metabolism)


Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings

Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings (Circulation)


Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study

Lockdown determined a relevant short-term metabolic worsening in approximately one-fourth of previously well-controlled type 2 diabetic individuals; pre-lockdown triglycerides were the only parameter able to predict such derangement of glucose control (Acta Diabetologica)


National Diabetes Audit, Non-Diabetic Hyperglycaemia, 2019- 2020, Diabetes Prevention Programme, Data Release

This short report uses data collected from GP practices alongside the National Diabetes Audit (NDA) for the period January 2019 to March 2020 inclusiv (NHS Digital)


Type 1 and type 2 diabetes after gestational diabetes: a 23 year cohort study

All women with GDM should be intensively monitored for a decade, after which the risk for type 1 diabetes is minimal. However, the incidence of type 2 diabetes remains linear, and therefore individualised lifelong follow-up is recommended (Diabetologia)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2020 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp